drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Investigational HER2-targeted monoclonal antibody administered IV every 3 weeks; likely inhibits HER2/ERBB2 signaling and mediates Fc-dependent cytotoxicity (ADCC/ADCP).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
IAH0968 is a HER2-targeted monoclonal antibody that binds ERBB2 on tumor cells, inhibits HER2 receptor activation and downstream PI3K/AKT and RAS/MAPK signaling to reduce proliferation, and recruits FcγR-expressing immune cells to mediate ADCC and ADCP.
drug_name
IAH0968
nct_id_drug_ref
NCT05991518